http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1363673-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a36318e68cbe30aa9f77314bc1621137 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 |
| filingDate | 2001-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39a78eacdea02aa733b3962bd8a09060 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d9ac6af5b581e03a6297ff7963901b6 |
| publicationDate | 2003-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1363673-A2 |
| titleOfInvention | Compositions for reducing side effects in chemotherapeutic treatments |
| abstract | A pharmaceutical compound and a process for making the compound is provided where the compound includes a therapeutic agent, a spacer and a galactose, the spacer being covalently linked to the therapeutic agent at a first site on the spacer and covalently linked to the galactose by an ether bond at a second site on the spacer to form a conjugate. The conjugate may be used to treat a subject suffering from a medical condition, so as to reduce the side effects associated with the therapeutic agent by administering an effective dose of the conjugate to the subject so that the side effects in the subject are less then they would have been with the unconjugated therapeutic agent. |
| priorityDate | 2000-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 294.